Dr. Vincent Rajkumar discussed newly diagnosed multiple myeloma in transplant-eligible patients, noting 20–25% are now high risk. Quadruplet regimens like Dara-VRd show strong outcomes, with 90% 4-year survival. Early transplant is key for high-risk cases; lenalidomide remains standard for maintenance.